Loading stock data…
$1.18-0.02 (-1.67%)
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
Geron Corporation in the Healthcare sector is trading at $1.18 with a market capitalization of $880M. Wall Street consensus targets $4.25 (4 analysts), implying a +260.2% move over the next 12 months. The stock is currently near its 52-week low of $1.04, remaining 18.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $57.48M↑ | $51.84M↑ | $48.02M↑ | $47.23M↓ | $49.04M |
| Gross Profit | $48.24M↓ | $50.15M↑ | $46.71M↑ | $46.18M↓ | $47.85M |
| Operating Income | -$12.65M↓ | -$236,000↑ | -$8.51M↑ | -$13.89M↓ | -$12.45M |
| Net Income | -$16.68M↓ | -$3.64M↑ | -$28.86M↓ | -$18.43M↓ | -$16.38M |
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to...